Director Bai Tao increased his holdings of CHINA QINFA (00866) by 1 million shares at a price of approximately HK$1.87 per share.
The latest data from the Hong Kong Stock Exchange shows that on May 21, executive director Bai Tao increased his holdings of China Qinfa (00866) by 1 million shares, with a price of 1.8679 Hong Kong dollars per share, for a total amount of 1.8679 million Hong Kong dollars.
The latest data from the Hong Kong Stock Exchange shows that on May 21, executive director Bai Tao increased his holdings of CHINA QINFA (00866) by 1 million shares, with a price of 1.8679 Hong Kong dollars per share, totaling 1.8679 million Hong Kong dollars. The latest number of shares held after the increase is 61 million shares, with a shareholding ratio of 2.32%.
Related Articles
New Stock News | Rongtai Pharmaceutical submits a second application to the Hong Kong Stock Exchange, becoming China's third-largest provider of digital marketing and supply chain services for the outpatient pharmaceutical market.
New IPO news: Xiangdao Travel submitted a second application to the Hong Kong Stock Exchange, attracting key industry chain investors such as Momenta, Gaode, and Contemporary Amperex Technology.
New Stock News | Innovative biopharmaceutical company Sinocelltech Inc. (688520.SH) files for listing on the Hong Kong Stock Exchange with a gross profit margin of over 90% for three consecutive years.
New Stock News | Rongtai Pharmaceutical submits a second application to the Hong Kong Stock Exchange, becoming China's third-largest provider of digital marketing and supply chain services for the outpatient pharmaceutical market.
New IPO news: Xiangdao Travel submitted a second application to the Hong Kong Stock Exchange, attracting key industry chain investors such as Momenta, Gaode, and Contemporary Amperex Technology.
New Stock News | Innovative biopharmaceutical company Sinocelltech Inc. (688520.SH) files for listing on the Hong Kong Stock Exchange with a gross profit margin of over 90% for three consecutive years.
